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Purpose: To present an autonomous intraocular pressure (IOP) measurement technique 
using a wireless implantable transducer (WIT) and a motion sensor.
Methods: The WIT optical aid was implanted within the ciliary sulcus of a normotensive  rabbit 
eye after extracapsular clear lens extraction. An autonomous wireless data system (AWDS) 
comprising of a WIT and an external antenna aided by a motion sensor provided continuous IOP 
readings. The sensitivity of the technique was determined by the ability to detect IOP changes 
resulting from the administration of latanoprost 0.005% or dorzolamide 2%, while the reliability 
was determined by the agreement between baseline and vehicle (saline) IOP.
Results: On average, 12 diurnal and 205 nocturnal IOP measurements were performed 
with latanoprost, and 26 diurnal and 205 nocturnal measurements with dorzolamide. No 
difference was found between mean baseline IOP (13.08±2.2 mmHg) and mean vehicle IOP 
(13.27±2.1 mmHg) (P=0.45), suggesting good measurement reliability. Both antiglaucoma 
medications caused significant IOP reduction compared to baseline; latanoprost reduced 
mean IOP by 10% (1.3±3.54 mmHg; P,0.001), and dorzolamide by 5% (0.62±2.22 mmHg; 
P,0.001). Use of latanoprost resulted in an overall twofold higher IOP reduction compared 
to dorzolamide (P,0.001). Repeatability was ±1.8 mmHg, assessed by the variability of con-
secutive IOP measurements performed in a short period of time (#1 minute), during which 
the IOP is not expected to change.
Conclusion: IOP measurements in conscious rabbits obtained without the need for human 
interactions using the AWDS are feasible and provide reproducible results.
Keywords: IOP, pressure transducer, wireless, MEMS, implant, intraocular
Introduction
Currently, intraocular pressure (IOP) measurement in animals is performed using 
handheld tonometers that require animal immobilization or sedation. The main dis-
advantages of these techniques are the use of indirect methods to measure IOP, the 
induced animal stress that can result in artificial IOP elevation, and the use of sedatives 
that can lower IOP.1,2 Alternatively, telemetric measurement in undisturbed rabbits 
were previously attempted in the late 1990s using telemetric transducers implanted 
subcutaneously on the dorsal neck, between the scapulae.1,3 These sensors were 
connected to the eye using a fluid-filled catheter. Both studies demonstrated diurnal 
rhythm in IOP, with rising IOP in night hours and falling IOP during the day hours. 
However, both arrangements required extraocular implantation of the transducer, 
raising issues about the practicality of the procedure and the possible long-term risk 
for infection.
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Recent advances in electronics and biomaterials have 
enabled the use of more sophisticated, miniaturized, and com-
pletely implantable IOP transducers for evaluating glaucoma 
drugs, which aim to reduce IOP.4–6 In 2000, a free-standing 
intraocular silicone implant, encapsulated into a polydimeth-
ylsiloxane polymer, was implanted for IOP measurements 
in conscious rabbits.7 The authors proposed that this device 
could serve as a functioning model of a telemetric IOP sensor 
for integration into an artificial intraocular lens, exhibiting 
a 0.9 to 0.99 correlation to pneumatonometry reading. In a 
more recent study,8 an existing implantable pressure trans-
ducer was used for high frequency continuous IOP measure-
ments in nonhuman primates. The transducer was fixated 
at the lateral orbital wall, and a 23-gauge silicone tube was 
used to deliver aqueous humor from the anterior chamber 
to a fluid reservoir on the intraorbital side of the transducer. 
The extraocular part of the transducer was connected via a 
wire to the data acquisition and transmitter unit, which was 
implanted in the abdominal muscle wall. Continuous IOP 
measurements were acquired for 4 consecutive days before 
failure of the transducer.
Recently, our group implanted a fully encapsulated IOP 
transducer in rabbit eyes.9 The novelty of this device was 
based on the integration of the electronics, such as the pres-
sure transducer, transmitter antenna, and power electronics, 
on a chip that was implanted into the eye and required no 
further implantable extraocular electronics. Despite the tech-
nological advancements and the simplification of the surgical 
procedure, human interaction for animal immobilization or 
sedation was required. IOP measurements were obtained 
using a handheld IOP reader, thus inducing IOP measurement 
artifacts and limiting the number of IOP measurements that 
could be taken per day.5,6,10
This study extends our previous work9 and presents an 
autonomous wireless data system (AWDS) that measures 
IOP without human interaction. The sensitivity and reliability 
of this experimental paradigm is assessed in vivo with and 
without the use of IOP-lowering agents.
Materials and methods
animal iOP study
The study was approved by the Massachusetts Eye and Ear 
Infirmary Animal Care Committee (Boston, MA, USA) and 
adhered to the Association for Research in Vision and Oph-
thalmology Statement for the Use of Animals.  Implantation 
of a wireless IOP transducer was performed in a New 
Zealand White rabbit (Covance Inc., Dedham, MA, USA), 
housed in an individual cage under standard conditions of 
nutrition, humidity, and temperature. The rabbit was kept 
under alternating 12-hour light and 12-hour dark cycles. The 
wireless implantable IOP transducer (WIT) was implanted 
through a 10-mm limbal incision and into the ciliary sulcus 
of the left eye following the extracapsular extraction of the 
crystalline lens.
The AWDS was comprised of a WIT (Implandata 
Ophthalmics GmbH, Hannover, Germany), a data acquisi-
tion unit, a coil antenna, and a camera motion sensor. The 
AWDS design allowed for autonomous IOP measurements, 
thus avoiding the animal’s stress, sedation, and aberrant 
IOP recordings. The device integrated a pressure sensor, 
a temperature sensor, an identification encoder, an analog-
to-digital converter, and telemetry into a single implantable 
microchip. The outside diameter of the encapsulated implant 
was 11.3 mm, with an inside diameter of 7 mm, a thickness 
of 0.9 mm, and a weight of 0.1 g. The circular device was 
hermetically encapsulated in a biocompatible, platinum-
cured silicone rubber material that contains an open central 
aperture.
The pressure sensor was made by an array of plate capaci-
tors in parallel configuration: one rigid plate and one flex-
ible plate. The distance between the two plates derived the 
capacitive charge. Pressure acting on the capacitors caused 
plate deflection, thus changing the capacitance. This change 
in capacitance was analyzed and translated to IOP using a 
proprietary algorithm integrated in the data acquisition unit.
Communication between the implant and the data acqui-
sition unit was achieved wirelessly using an external radio 
frequency antenna (communication link at 13.56 MHz). The 
data acquisition device was designed to acquire ten IOP mea-
surements per second, average these measurements, and save 
the results to a memory card. Continuous IOP measurements 
were automatically performed as long as the eye was main-
tained within the effective antenna range. Measurements were 
triggered by a motion sensor connected to the data acquisition 
unit. Both the antenna and the motion sensor were placed in 
the cage pointing at the water bottle (Figure 1). When the 
rabbit drank, the motion sensor sent a triggering signal to the 
data acquisition unit to energize the implant and to acquire 
IOP measurements. The data was stored in a memory card 
within the data acquisition unit and contained a unique code 
with a time and date stamp. The data acquisition unit and the 
motion sensor were housed in a polymethylmethacrylate box 
for protection.
At the completion of each 5-week study cycle and during 
the 2-week washout period, the memory card was removed 
and replaced. Thus, human interaction was minimized to drop 
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administration only, and IOP measurements were obtained 
without the need for anesthesia, caretaker involvement, and 
the stress of animal manipulation.
The IOP sensitivity of the proposed design was evaluated 
using two antiglaucoma agents, latanoprost, and dorzolamide. 
Each agent was administered separately, followed by a wash-
out period of 1 month before introducing the second agent. 
A 1-month washout period was used based on the design of 
analogous published studies.11–15 Each study cycle (includ-
ing weekends) involved 1 week of baseline IOP measure-
ments without drop administration, 2 weeks of saline drop 
(vehicle) administration twice daily, 2 weeks of latanoprost 
0.005% (Xalatan®, Pfizer, New York, NY, USA) in the morn-
ing and saline in the evening, and 2 weeks of dorzolamide 
2% (Trusopt®, Merck & Co, Inc, Whitehouse Station, NJ, 
USA) one drop twice daily. Clinically, dorzolamide was 
Motion sensor Water bottle Antenna
Drinking
cannula
Poly(methylmethacrylate)
housing box with hole for
rabbit’s head
Intraocular implantable
pressure transducer
Rabbit’s
cage
Figure 1 schematic diagram of the wireless iOP acquisition technique.
Notes: a motion sensor (left) is used to trigger measurements each time the rabbit drinks from the water bottle (center). a wireless coil antenna (right), placed next to 
the eye with the implanted transducer, measures the iOP each time the motion sensor triggers a signal. all parts are housed in a polymethylmethacrylate box for protection 
and arranged in a way to optimize the quality of the signal. This technique provides autonomous iOP measurements, avoiding animal stress from human interaction and thus 
artificial IOP aberrations.
Abbreviation: iOP, intraocular pressure.
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 administered twice a day and latanoprost was administered 
once a day, in the mornings. Saline was administered in the 
evenings to account for the confounding stress that could 
be induced by differences in drop administration between 
latanoprost and dorzolamide. Thus, the evening saline drop 
in the latanoprost study was added for consistency reasons, 
equalizing the frequency of human interaction with both 
drugs.
The mean IOP reduction by each agent was calculated 
using the following formula:16
IOP reduction = IOP
agent
 – IOP
baseline
 ± SD2
agent
 + SD2
baseline 
(1)
The intrasession IOP repeatability was assessed as fol-
lows: Several random time points were selected, all having 
at least eight or more consecutive IOP measurements within 
1 minute period of time. IOP standard deviation (SD) was 
calculated for each time point, and the mean SD was calcu-
lated by averaging the SD from all time points. Since IOP 
is unlikely to change within a minute, IOP variations were 
attributed to the transducer’s repeatability.17 All data were 
at least 2 hours after drop administration in order to secure 
drug effect and animal relaxation.18
statistical analysis
All measurements were analyzed using Statistical Package 
for the Social Sciences, version 13.0 (IBM Corporation, 
Armonk, NY, USA). The normality of the sample was 
evaluated using Kolmogorov–Smirnov and Shapiro–Wilk 
tests. Quantitative variables were expressed as mean ± SD, 
and qualitative variables were expressed as frequencies and 
percentages. Analysis of variance (ANOVA) was used to 
evaluate differences in the IOP, and statistical significance 
was considered for P-value ,0.05. Bonferroni correction 
was applied to reduce the alpha-level error to P=0.02, for 
multiple comparisons between baseline, vehicle, and treat-
ment IOP. Polynomial equations (fifth order) were employed 
to reconstruct the circadian IOP rhythm from the point 
measurements.
Results
implantation of the transducer
The wireless IOP transducer was implanted in the rabbit 
18 months prior to this study, during which time the first 
study was performed.9 During this period, IOP measure-
ments were routinely compared to intracameral manometry 
to ensure that there was no “drift” in IOP measurements, 
a problem frequently observed with IOP transducers.3,8,9 
Three months prior to this study, the transducer was 
calibrated using intracameral manometry. The rabbit was 
anesthetized and a 21-gauge needle filled with balanced 
salt solution was inserted into the eye. The other end of 
the needle was connected to a pressure transducer (Har-
vard Apparatus, Holliston, MA, USA) measuring the IOP, 
as described previously.9 Additional measurements using 
TonoPen (Reichert Technologies, Depew, NY, USA) were 
performed 1 week prior to the study to ensure the func-
tionality of the transducer. The general ocular health of the 
animal was assessed and recorded daily using the operating 
microscope. The intraocular structures appeared to be intact, 
with no obvious changes in the myelinated optic nerves 
between the eyes.
iOP measurements
In order to measure IOP, the data acquisition system and 
the motion sensor were securely mounted on the cage, with 
the latter pointing towards the water bottle (Figure 1). IOP 
measurements were autonomously triggered by the motion 
sensor each time the rabbit attempted to drink water from 
the bottle, thus avoiding human interaction and animal stress 
that could result in unwanted IOP fluctuations. Twenty-two 
percent of the IOP measurements were diurnal (7 am–7 pm) 
and 78% were nocturnal (7 pm–7 am) (Figure 2A and B). 
A similar rhythm was also obtained with vehicle treatment 
(Figure 2C). Overall, diurnal IOP (median ± standard error) 
was 11±0.138 and nocturnal IOP was 12±0.102 (P=0.563; 
Mann–Whitney U test). Diurnal IOP measurements were 
lower by 8.3% compared to nocturnal measurements, a per-
centile variation that is not statistically significant.  Nocturnal 
activity was increased, as evidenced by the increased fre-
quency in IOP measurements; this result is in concordance 
with previously published studies using telemetry.3,4 The 
mean intrasession IOP variability, assessed using vehicle 
treatment (saline drops), was ±1.8 mmHg (mean IOP mea-
surements; n=10). Assuming that vehicle treatment should 
not change IOP unless stress is induced during measure-
ments, vehicle IOP measurements were compared to the 
previously measured baseline IOP to elucidate the effect 
of eye drop administration in IOP. Average baseline IOP 
was 13.08±2.2 mmHg (n=99 measurements) and IOP with 
vehicle treatment was 13.27±2.1 mmHg (n=185 measure-
ments), which was not significantly different (P.0.45), 
suggesting that applying drops to the ocular surface had 
no influence on IOP outcome. Thus, further evaluation was 
undertaken, as explained on next page, to assess the ability 
of the AWDS to detect IOP variations.
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measured and compared to the corresponding baseline IOP. 
On  average, 12 diurnal and 205 nocturnal IOP measurements 
were obtained with latanoprost, and 26 diurnal and 205 noc-
turnal measurements were obtained with dorzolamide. The 
frequencies in diurnal and nocturnal IOP measurements were 
comparable to baseline and vehicle treatment.
Both antiglaucoma agents caused significant IOP reduc-
tion compared to baseline. Use of latanoprost resulted in 
a 10% IOP reduction from baseline (1.3±3.54 mmHg; 
P,0.001, ANOVA), and dorzolamide resulted in a 5% 
reduction (0.62±2.22 mmHg; P,0.001, ANOVA) (Table 1). 
 Diurnal IOP was lower than nocturnal for both agents; 
however, this difference was not statistically significant 
(diurnal vs nocturnal IOP: latanoprost P.0.318; dorzol-
amide P.0.689) (Figure 3). The highest IOP measurements 
were recorded between 1 am–3 am, and the lowest between 
9 am–12 pm. Overall, IOP reduction with latanoprost was 
significantly higher compared to dorzolamide (P,0.001).
Discussion
In this study, we introduce a novel technique for obtaining 
autonomous IOP measurements in rabbits. Telemetric IOP 
measurements were obtained over an 8-week period, thus 
preventing study-related IOP fluctuations due to animal 
restraints, sedatives, and anesthesia,1,19,20 which have been 
shown to influence the validity of IOP measurements.21 In 
addition, the implementation of this technique provides mea-
surements of the nocturnal IOP, an otherwise laborious task 
using standard telemetry methods involving human aid. This 
study is a continuation of a previous published work using the 
aforementioned implantable transducer9 with the addition of 
a motion sensor for autonomous IOP measurements.
This pilot study was carried out in a single rabbit, and 
served as a proof of concept for the implementation of 
autonomous IOP measurements with telemetry. We assessed 
the repeatability of the technique by measuring the intrases-
sion IOP variability. To do so, we calculated the SD for at 
least eight consecutive IOP measurements taken during a 
60-second interval. The mean intrasession IOP variability 
was ±1.8 mmHg, a value lower than the variability seen with 
the Goldmann tonometer (±2.3–3.7 mmHg),21–24 ocular blood 
flow tonograph (±3.7 mmHg), TonoPen (±4.3 mmHg) or the 
Canon noncontact tonometer (±3.2 mmHg).21 Our results 
suggest that AWDS exhibits good repeatability, with the 
ability to detect small IOP changes. Similar results would 
be impossible to obtain with traditional tonometers due to 
their higher intrasession variability. The ability to detect 
small IOP changes is critically important in animal research, 
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Figure 2 Circadian iOP variation with (A) latanoprost, (B) dorzolamide, and (C) 
vehicle administration.
Notes: The data points represent independent iOP measurements during 2 weeks 
of measurements. The dotted black line represents the polynomial fit (5th order) of 
the data set and the two red lines is the boundary between 1 ± standard deviation 
from iOP mean.
Abbreviations: h, hours; iOP, intraocular pressure; M, minutes.
iOP measurements using antiglaucoma 
medication
The sensitivity of the AWDS to detect IOP variations result-
ing from the application of latanoprost and dorzolamide was 
assessed separately. Each agent was given for 2 weeks, and 
IOP measurements were obtained throughout this period. 
The magnitude of IOP reduction with each agent was 
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Table 1 iOP reduction with placebo, latanoprost 0.005%, and dorzolamide 2% compared to baseline
N 95% CI of mean Mean SD P-value compared to baseline IOP
Lower bound Upper bound
Vehicle (saline) 86 -0.262 0.80 0.27 2.48 .0.5
latanoprost 254 -1.57 -1.03 -1.32 2.18 ,0.001*
Dorzolamide 284 -0.81 -0.44 -0.62 1.55 ,0.001*
Notes: A summary of all IOPs taken throughout the study. *Statistically significant difference at 0.05 (comparison of the two groups).
Abbreviations: CI, confidence interval; N, number of IOP measurements; IOP, intraocular pressure; SD, standard deviation.
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Figure 3 Diurnal and nocturnal iOP reduction with latanoprost and dorzolamide.
Notes: no difference between diurnal and nocturnal iOP with latanoprost (P.0.318) or dorzolamide (P.0.683). However, latanoprost causes significantly higher IOP 
reduction that dorzolamide in both diurnal (P,0.003) and nocturnal (P,0.002) IOP measurements. *Statistically significant difference compared to baseline IOP (t-test).
Abbreviations: IOP, intraocular pressure; NS, nonstatistically significant difference (t-test); CI, confidence interval.
where anatomical and biological differences compared to 
humans might change the magnitude of hypotonic efficacy 
of certain drugs.25,26
The reliability of the technique was determined by com-
paring baseline and vehicle IOP. No significant difference 
was found between baseline and vehicle IOP, suggesting that 
no IOP artifacts were introduced with the implementation 
of AWDS. Previous studies using telemetry have shown 
that animal handling or sedation results in IOP artifacts, 
even with vehicle drops administration.3,9,27 In addition, 
blinking and forced eyelid opening during examination can 
cause transient increases in IOP,4 and investigator experi-
ence can influence the reliability of IOP measurements.24 
In our study, IOP measurements were autonomously per-
formed, thereby eliminating the need for animal handling 
or  sedation. In addition, the reliability of the AWDS was 
further  validated by the agreement between baseline and 
vehicle IOP measurements.
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The sensitivity of the AWDS was evaluated in a normo-
tensive rabbit using two IOP-lowering drugs: dorzolamide 
and latanoprost. In this study, dorzolamide caused an IOP 
reduction of 0.6 mmHg (-5%, P,0.001), which is less 
than previously described (-2.6 mmHg or -17%)18 in nor-
motensive rabbits and normotensive humans (-3 mmHg or 
-19%).28 Latanoprost caused an IOP reduction of 1.3 mmHg 
(-10%, P,0.001), which is in agreement with a previous 
report of 1.5 mmHg (-13% to 17%) in normotensive rab-
bits.27 The IOP-lowering effect of latanoprost is known to 
be species dependent.25,26 In a different study, latanoprost 
has been shown to cause an IOP reduction of 26% in nor-
motensive humans, 16% in monkeys, and no change in 
rabbits.29
It is reasonable to believe that the reduced efficacy 
of latanoprost in rabbits can also be attributed to several 
comparative anatomical and biological differences, which 
are important considering the mechanism of action of the 
drug. Latanoprost is an ester analog of prostaglandin F2α 
that reduces IOP by increasing uveoscleral outflow.14 Thus, 
anatomical difference in the uveal or binding affinity differ-
ences in the prostanoid receptors between species can have 
a significant impact on the hypotonic effect of latanoprost. 
Therefore, the reduced hypotonic effect of latanoprost could 
be explained by the fact that normotensive rabbits have less 
uveoscleral outflow (3%–8%)30 than normotensive humans 
(25%).31,32 In addition, a reduced binding affinity by the 
prostanoid receptors in the nonpigmented ciliary epithe-
lial cells has been reported in rabbits.33 Furthermore, the 
observed hypotonic effect in rabbits could be attributed to 
the secondary effect of nitric oxide production, known to 
induce hyperemia, increased blood flow of the anterior uvea, 
and IOP reduction.34
In this study, we compared the lower diurnal IOP to 
the peak nocturnal IOP (3-hour time intervals). The high-
est diurnal IOP change was observed between 9 am and 
12 pm, with an 8.3% IOP reduction (-1 mmHg), com-
pared to nocturnal measurements between 1–3 am. This 
variation is not statistically significant, but is consistent 
with a previous study of rabbit diurnal IOP variation using 
pneumatonography,35 Interestingly, not all the rabbits in 
the pneumatonography study exhibited the same diurnal 
variations.35 In comparison to a previous study that reported 
a wide range of diurnal IOP variation in rabbits,1,35–40 the 
lower diurnal IOP variation observed in our study could be 
attributed to several factors. For instance, the baseline IOP 
was low, and could be indicative of a lower plasma corti-
costeroid level.36,41 Eyes with higher IOPs exhibit elevated 
levels of corticosteroids in the plasma,36 which could relate 
to higher IOP variations. Elevated corticosteroid levels in 
the plasma can be due to animal stress;42–46 a confounding 
factor that was minimized in the present study using the 
AWDS. Another differentiating factor in our study is that 
measurements were obtained telemetrically in an awake, 
unrestrained rabbit when its head approached the water 
bottle, thus ensuring consistency in body posture and mini-
mal sensory stimulation during measurements, which are 
known to cause transient IOP changes.38–40,47,48 Our results 
are similar to other diurnal IOP studies performed in awake 
rabbits.35–37 In contrast, diurnal telemetric IOP measure-
ments obtained in sleeping rabbits40 exhibited greater IOP 
variations.47–49 Elevated IOP in sleeping rabbits could be 
attributed to eyelid closure and increased abdominal pres-
sure in the resting position, which have been shown to result 
in an IOP elevation of 5 mmHg.47–49
We conclude that the AWDS can provide IOP measure-
ments in rabbits with high sensitivity and low intrases-
sion IOP variability. Our technique overcomes previous 
limitations, thus providing reliable measurements critically 
important in the analysis of new antiglaucoma drugs.1,50 In 
addition, circadian IOP rhythm was obtained under similar 
diurnal and nocturnal conditions, including body posture, 
eyelid position, and minimal animal stress, thus decreasing 
IOP artifacts in our telemetric measurements. The imple-
mentation of the AWDS can improve the reliability of data 
acquisition and ameliorate the use of animal models in 
glaucoma research.
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